China SXT Pharmaceuticals, Inc.
SXTC
$2.61
-$0.02-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 313.30K | 313.30K | 455.70K | 455.70K | 414.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 313.30K | 313.30K | 455.70K | 455.70K | 414.70K |
| Cost of Revenue | 262.40K | 262.40K | 339.40K | 339.40K | 347.40K |
| Gross Profit | 50.90K | 50.90K | 116.30K | 116.30K | 67.40K |
| SG&A Expenses | 3.22M | 3.22M | 1.14M | 1.14M | 386.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.48M | 3.48M | 1.48M | 1.48M | 733.90K |
| Operating Income | -3.17M | -3.17M | -1.02M | -1.02M | -319.10K |
| Income Before Tax | -3.18M | -3.18M | -1.25M | -1.25M | -401.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.18M | -3.18M | -1.25M | -1.25M | -401.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.18M | -3.18M | -1.25M | -1.25M | -401.30K |
| EBIT | -3.17M | -3.17M | -1.02M | -1.02M | -319.10K |
| EBITDA | -3.15M | -3.15M | -1.01M | -1.01M | -284.90K |
| EPS Basic | -4.12 | -4.12 | -76.79 | -76.79 | -- |
| Normalized Basic EPS | -2.57 | -2.57 | -47.99 | -47.99 | -- |
| EPS Diluted | -4.12 | -4.12 | -76.79 | -76.79 | -- |
| Normalized Diluted EPS | -2.57 | -2.57 | -47.99 | -47.99 | -- |
| Average Basic Shares Outstanding | 773.50K | 773.50K | 16.30K | 16.30K | -- |
| Average Diluted Shares Outstanding | 773.50K | 773.50K | 16.30K | 16.30K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |